Clinical Observation of Early Application of Tirofiban Combined with Different Lipid-regulating Drugs Inter-vention in Elderly Patients with Coronary Heart Disease
10.6039/j.issn.1001-0408.2015.29.30
- VernacularTitle:早期使用替罗非班联合不同调脂药对老年冠心病患者经冠状动脉介入治疗的临床观察
- Author:
Jie CHEN
;
Liwei FENG
- Publication Type:Journal Article
- Keywords:
Tirofiban;
Atorvastatin;
Probucol;
Elderly;
Coronary heart disease;
Percutaneous coronary intervention
- From:
China Pharmacy
2015;(29):4118-4120,4121
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe short-term efficacy and safety of early use of tirofiban combined with different lipid-regu-lating drugs percutaneous coronary intervention(PCI)in elderly patients with coronary heart disease. METHODS:562 elderly pa-tients with coronary heart disease underwent selective PCI were selected and randomly divided into atorvastatin group and probucol group,with 281 cases in each group. Both group received routine treatment;atorvastatin group was additionally given tirofiban combined with Atorvastatin tablet,and probucol group was additionally given irofiban combined with Probucol tablet. Clinical indi-cators and main adverse cardiac event(MACE)were compared between 2 groups before and after treatment. RESULTS:After treat-ment,3 level of thrombolysis in myocardial infarction(TIMI)in atorvastatin group accounted for 69.4%,which was significantly lower than 95.7% of probucol group,with statistical significance(P<0.05). After 12h treatment,CK,2 groups had lower CK-MB and LVEF and higher cTnI;LVEF decrease of atorvastatin group was more significant,with statistical significance(P<0.05);af-ter 8 weeks of treatment,NO,NO/ET-1,GSH,GSH/GSSG of probucol group were increased significantly,and ET-1,GSSG and Eh decreased significantly;above indexes of atorvastatin group had no significant change,there was statistical significance between 2 groups(P<0.05). The incidence of MACE in atorvastatin group and probucol group were 21.7% and 21.4%,there was no sig-nificant difference (P>0.05). CONCLUSIONS:Tirofiban combined with different lipid-regulating drugs can effectively improve the prognosis of elderly patients with coronary heart disease after PCI operation with good safety,but tirofiban combined with pro-bucol has more obvious therapeutic effect.
